Skip to main content
Journal cover image

Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.

Publication ,  Journal Article
Goodnough, LT; Smith, PK; Levy, JH; Poston, RS; Short, MA; Weerakkody, GJ; LeNarz, LA
Published in: J Thorac Cardiovasc Surg
April 2013

OBJECTIVE: Coronary artery bypass grafting-related bleeding and associated transfusion is a concern with dual antiplatelet therapy in patients with acute coronary syndromes. The objective of the present study was to characterize a potential risk-adjusted difference in transfusion requirements between prasugrel and clopidogrel cohorts. METHODS: The data from 422 patients undergoing isolated coronary artery bypass grafting from the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 were analyzed retrospectively. RESULTS: We found no difference in baseline transfusion risk scores between cohorts. As predicted, the number of units of red blood cells transfused perioperatively correlated with the transfusion risk score (P < .0001). Overall, the 12-hour chest tube drainage volumes and platelet transfusion rates in the prasugrel cohort were significantly greater. However, no statistically significant differences were found in the number of red blood cell transfusions, total hemostatic components transfused, or total blood donor exposure. A significantly greater number of platelet units were transfused postoperatively in the prasugrel patients who underwent surgery within 5 days or less after withdrawal of drug. In an analysis adjusted for the predicted risk of mortality, total donor exposure was not associated with increased mortality. CONCLUSIONS: The use of prasugrel compared with clopidogrel was associated with greater 12-hour chest tube drainage volumes and platelet transfusion rates but without any significant differences in red blood cell transfusions, total hemostatic components transfused, or total blood donor exposure.

Duke Scholars

Published In

J Thorac Cardiovasc Surg

DOI

EISSN

1097-685X

Publication Date

April 2013

Volume

145

Issue

4

Start / End Page

1077 / 1082.e4

Location

United States

Related Subject Headings

  • Ticlopidine
  • Thiophenes
  • Risk Factors
  • Retrospective Studies
  • Respiratory System
  • Prasugrel Hydrochloride
  • Platelet Transfusion
  • Platelet Aggregation Inhibitors
  • Piperazines
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goodnough, L. T., Smith, P. K., Levy, J. H., Poston, R. S., Short, M. A., Weerakkody, G. J., & LeNarz, L. A. (2013). Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. J Thorac Cardiovasc Surg, 145(4), 1077-1082.e4. https://doi.org/10.1016/j.jtcvs.2012.07.059
Goodnough, Lawrence T., Peter K. Smith, Jerrold H. Levy, Robert S. Poston, Mary A. Short, Govinda J. Weerakkody, and LeRoy A. LeNarz. “Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.J Thorac Cardiovasc Surg 145, no. 4 (April 2013): 1077-1082.e4. https://doi.org/10.1016/j.jtcvs.2012.07.059.
Goodnough LT, Smith PK, Levy JH, Poston RS, Short MA, Weerakkody GJ, et al. Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. J Thorac Cardiovasc Surg. 2013 Apr;145(4):1077-1082.e4.
Goodnough, Lawrence T., et al. “Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.J Thorac Cardiovasc Surg, vol. 145, no. 4, Apr. 2013, pp. 1077-1082.e4. Pubmed, doi:10.1016/j.jtcvs.2012.07.059.
Goodnough LT, Smith PK, Levy JH, Poston RS, Short MA, Weerakkody GJ, LeNarz LA. Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. J Thorac Cardiovasc Surg. 2013 Apr;145(4):1077-1082.e4.
Journal cover image

Published In

J Thorac Cardiovasc Surg

DOI

EISSN

1097-685X

Publication Date

April 2013

Volume

145

Issue

4

Start / End Page

1077 / 1082.e4

Location

United States

Related Subject Headings

  • Ticlopidine
  • Thiophenes
  • Risk Factors
  • Retrospective Studies
  • Respiratory System
  • Prasugrel Hydrochloride
  • Platelet Transfusion
  • Platelet Aggregation Inhibitors
  • Piperazines
  • Humans